Episteme Prognostics, Inc. — SEC Form D Filing
Episteme Prognostics, Inc. filed an SEC Form D on September 4, 2026, reporting $5.09M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 4, 2026
- Amount reported
- $5.09M
- Round stage
- Series A, inferred from the $5.09 million raised which represents a typical early-institutional round size required to fund clinical validation studies in the biotechnology sector.
- Industry
- Biotechnology
- Website
- https://epistemeprognostics.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Oncologists and clinicians lack precise, molecular-level predictive tools to accurately forecast disease progression and patient response to specific therapies.
Solution
Episteme Prognostics develops advanced molecular prognostic assays and machine learning-driven biomarker platforms to predict patient outcomes and guide personalized treatment selection.
Why now
Recent advancements in high-throughput genomic sequencing and artificial intelligence now allow for the rapid, cost-effective identification of complex prognostic signatures.
Source: SEC EDGAR Form D filing